Clinical Trial Update: A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Pfizer conducted a one-year Phase 3 trial to evaluate the effects and safety of CP-690,550 (tofacitinib) in adults with moderate to severe chronic plaque psoria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-19